BioInvent Partners with MSD for BI-1910 and KEYTRUDA Combination Trial

BioInvent, a Swedish biotech firm specializing in innovative cancer immunotherapy antibodies, has entered into a partnership with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., for a Phase 1/2a clinical trial. The trial will assess the efficacy of BioInvent's monoclonal antibody, BI-1910, when used in conjunction with Merck's KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy. MSD will supply KEYTRUDA for the study, which is set to take place across the United States and Europe and is designed to be adaptive for optimal dosage adjustments.

BI-1910 represents BioInvent's second venture into the clinical development of tumor necrosis factor receptor 2 (TNFR2) agonist antibodies, following the ongoing Phase 2a trials of BI-1808. The company's proprietary F.I.R.S.T™ technology facilitated the selection of both antibodies, which are considered potential best-in-class candidates. The solo administration phase of BI-1910's clinical trial began in December 2023, with preliminary results anticipated by the end of 2024.

Martin Welschof, CEO of BioInvent, expressed enthusiasm for the collaboration, highlighting the company's expertise in TNFR2 biology and its ongoing efforts to advance two distinct monoclonal antibodies through clinical trials. This initiative marks the fifth product in BioInvent's clinical development pipeline, underscoring the company's ability to identify novel therapeutic targets for cancer treatment.

BioInvent is a clinical-stage company listed on the Nasdaq Stockholm exchange, with a focus on discovering and developing first-in-class immuno-modulatory antibodies. The company currently has five drug candidates in Phase 1/2 trials, targeting both hematological cancers and solid tumors. Revenue is derived from research collaborations, licensing agreements with leading pharmaceutical companies, and the production of antibodies for third parties through its manufacturing division.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!